Cumberland Pharmaceuticals CPIX Product — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cumberland Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Cumberland Pharmaceuticals’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cumberland Pharmaceuticals's product — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cumberland Pharmaceuticals's product — revenue?
- Cumberland Pharmaceuticals (CPIX) reported product — revenue of $10.1M in Q4 2025.
- How has Cumberland Pharmaceuticals's product — revenue changed year-over-year?
- Cumberland Pharmaceuticals's product — revenue increased by 10.6% year-over-year, from $9.13M to $10.1M.
- What is the long-term trend for Cumberland Pharmaceuticals's product — revenue?
- Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's product — revenue has grown at a 3.6% compound annual growth rate (CAGR), from $35.05M to $40.4M.
- What does product — revenue mean?
- This metric represents the total gross sales generated from the company's portfolio of branded prescription pharmaceutical products. It reflects the commercial success of the firm's hospital acute care, gastroenterology, rheumatology, and oncology product lines. Tracking this revenue stream provides insight into the market adoption and competitive performance of the company's core specialty pharmaceutical offerings.